
Ellipses Pharma licences SRB22 from SunRock Biopharma
Under the agreement, British Ellipses Pharma Ltd has been granted global rights to develop and commercialise SBR22 (which it renamed to EP0017) from...

Single-use market to reach $20.8bn by 2026
The "Global Forecast 2026" comprises Media Bags and containers, Bioreactors, Mixers, Assemblies, Applications (Cell Culture, Mixing,...

GeNeuro finds biologic against post-COVID syndrome
The results of a collaboration of GeNeuro with the FondaMental Foundation were presented at the Schizophrenia International Research Society (SIRS)...

Argenx SE to raise €637m
Last December, the Breda-based drugmaker got the green lightfrom the US FDA for its injectible anti-acetylcholin receptor antibody fragment...

Abliva decides on a SEK200m financing to fund Phase 2/3 study
Swedish Abliva is focussing on mitochondrial medicine, developing therapeutics for primary mitochondrial diseases, orphan indications of high unmet...

Four new autoantigens trigger multiple sclerosis
Despite considerable progress in the treatment of multiplesclerosis (MS), the disease still often leads to permanent neurological disability....

XNK Therapeutics AB raises €12.75m
XNK Therapeutics said it will use the proceeds to accelerate an investigator-initiateed open Phase II study with its autologous NK cell-based...